Lymphoma, T-Cell, Peripheral × Etoposide × Clear all
NCT00536601 2021-04-22

High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors

Roswell Park Cancer Institute

Phase NA Completed
174 enrolled 17 charts
NCT01408043 2019-06-14

Etoposide, Filgrastim, and Plerixafor in Improving Stem Cell Mobilization in Treating Patients With Non-Hodgkin Lymphoma

Case Comprehensive Cancer Center

Phase NA Terminated
25 enrolled 15 charts
NCT01110135 2017-05-24

Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple Myeloma

University of Washington

Phase 2 Completed
43 enrolled 5 charts
NCT01959477 2015-08-13

Dose Monitoring of Busulfan and Combination Chemotherapy in Hodgkin or Non-Hodgkin Lymphoma Undergoing Stem Cell Transplant

Case Comprehensive Cancer Center

Phase EARLY_PHASE1 Completed
33 enrolled
NCT01769911 2015-05-07

Genetically Modified Peripheral Blood Stem Cell Transplant in Treating Patients With HIV-Associated Non-Hodgkin or Hodgkin Lymphoma

Fred Hutchinson Cancer Center

Phase NA Withdrawn
NCT00101205 2014-02-24

Oxaliplatin, Ifosfamide and Etoposide in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma

National Cancer Institute (NCI)

Phase 1 Terminated
40 enrolled